TMS denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for tms are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UHC Denied TMS as "Not FDA-Approved" — and How to Rebut It Directly

Transcranial magnetic stimulation received FDA clearance for major depressive disorder that has not responded adequately to antidepressant treatment, and the FDA has cleared additional indications since that initial clearance. A "not FDA-approved" or "not FDA-cleared" denial from UnitedHealthcare almost always means one of the following: the TMS device or the specific indication was not identified clearly in the prior-authorization submission; UHC's reviewer applied an outdated or blanket experimental exclusion without checking current clearance status; or the denial was generated automatically by a system that flagged TMS under an old policy. The rebuttal is straightforward but must be documented in writing.

## The Federal Appeal Framework

Under ACA §2719, non-grandfathered plans must provide internal appeal and independent external review. External review is particularly well-suited to regulatory-status disputes: independent reviewers assess whether a treatment has recognized regulatory clearance and whether a plan's denial correctly characterizes that status. The external-review window is generally available for roughly four months after the internal denial. Under ERISA §503, employer-sponsored plans must provide a full-and-fair review. An expedited appeal is available when your clinician certifies that delay would seriously jeopardize your health.

## What to Gather

• FDA 510(k) clearance letter for the specific TMS device to be used. This is the single most important document in this appeal. Your prescriber or the device manufacturer can supply it. Attach it as Exhibit A.
• The specific cleared indication. Document that your diagnosis and clinical profile fall within the indication for which the device is cleared, as described in the prescribing information and clearance letter.
• UHC's current coverage policy for TMS. Request the document by name. If UHC's own policy covers TMS for the cleared indication — which many UHC policies do — cite the relevant language directly in your appeal letter and argue that the denial misapplies the policy.
• Diagnosis and severity documentation. Formal psychiatric records confirming the diagnosis and current severity.
• Prior treatment history. Dated records of antidepressant trials with names, durations, and outcomes, establishing the treatment-resistant profile that the cleared indication requires.
• Prescriber medical-necessity letter. A signed letter specifically addressing the "not FDA-approved" characterization: citing the clearance, the cleared indication, and your clinical profile.

## Criteria-Mapping Structure

For each element of UHC's "not FDA-approved" denial rationale, provide a direct documentary rebuttal: regulatory status addressed by the clearance letter, indication addressed by your diagnosis records, and any other element addressed by your clinical history. Keep the table concise — one clear rebuttal per denial element.

## Next Step

File the internal appeal in writing before UHC's stated deadline. Attach the FDA clearance letter prominently. If denied internally, invoke external review in writing immediately.